Molecular pattern of ductal pancreatic cancer

Langenbeck's Archives of Surgery

Volumn 383, Issue 2, 1998, Pages 105-115

  Sirivatanauksorn, V ^a   Sirivatanauksorn, Y ^a   Lemoine, N R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Growth factor receptors; Growth factors; Oncogene; Pancreatic cancer; Tumour suppressor gene

Indexed keywords

CYCLIN DEPENDENT KINASE; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; MATRIX METALLOPROTEINASE; PLASMINOGEN ACTIVATOR; PROTEIN P16; PROTEIN P53; RAS PROTEIN; RETINOBLASTOMA PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

CANCER GENETICS; CANCER GROWTH; CANCER INVASION; GENE DISRUPTION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; METASTASIS; MOLECULAR GENETICS; ONCOGENE K RAS; PANCREAS CANCER; PANCREAS DUCT; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 0031684966     PISSN: 14352443     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004230050101     Document Type: Review

References (144)

1. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53:549-554
2. Shibata D, Capella G, Perucho M (1990) Mutational activation of the c-K-ras gene in human pancreatic carcinoma. Baillieres Clin Gastroenterol 4:151-169
3. Grunewald K, Lyons J. Frohlich A, Feichtinger H, Weger RA, Schwab G, Janssen JWG, Bartram CR (1989) High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 43:1037-1041
4. Smit VT, Boot AJ, Smits AM, Fleuren GJ, Cornelisse CJ, Bos JL (1988) KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 16:7773-7782
5. DiGiuseppe JA, Hruban RH, Offerhaus GJ, Clement MJ, van den Berg FM, Cameron JL, van Mansfeld AD (1994) Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma. Am J Pathol 144:889-895
6. Bos JL (1989) ras oncogenes in human cancer: a review. Cancer Res 49:4682-4689
7. Capella G, Cronauer Mitra S, Pienado MA, Perucho M (1991) Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors. Environ Health Perspect 93:125-131
8. th codon of the c-Ki-ras gene found in pancreatic cancers from Japanese patients. Jpn J Cancer Res 80:622-626
9. Fujii H, Egami H, Chaney W, Pour P, Pelling J (1990) Pancreatic ductal adenocarcinomas induced in Syriam hamsters by N-mtrosobis(2-oxopropyl) amine contain a c-Ki-ras oncogene with a point-mutated codon 12. Mol Carcinog 3:296-301
10. Malats N, Porta M, Corominas JM, Pinol JL, Rifa J, Real FX (1997) Ki-ras mutations in exocrine pancreatic cancer: association with clinico-pathological characteristics and with tobacco and alcohol consumption. Int J Cancer 70:661-667
11. Yanagisawa A, Kato Y, Ohtake K, Kitagawa T, Ohashi K, Hon M, Takagi K, Sugano H (1991) c-Ki-ras point mutations in ductectatic-type mucinous cystic neoplasms of the pancreas. Jpn J Cancer Res 82:1057-1060
12. Tada M, Omata M, Ohto M (1991) Ras gene mutations in intraductal papillary neoplasms of the pancreas. Analysis in five cases. Cancer 67:634-637
13. Hoshi T, Imai M, Ogawa K (1994) Frequent K-ras mutations and absence of p53 mutations in mucin-producing tumors of the pancreas. J Surg Oncol 55:84-91
14. Z'graggen K, Rivera JA, Compton CC, Pins M, Werner J, Fernandez del Castillo C, Rattner DW, Lewandrowski KB. Rustgi AK, Warshaw AL (1997) Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas. Ann Surg 226:491-500
15. Pavelic K, Hrascan R, Kapitanovic S, Vranes Z, Cabrijan T, Spaventi S, Korsic M, Krizanac S, Li YQ, Stambrook P. Gluckman JL, Pavelic ZP (1996) Molecular genetics of malignant insulinoma. Anticancer Res 16:1707-1717
16. Shibata D, Almoguera C, Forrester K, Dunitz J, Martin SE, Cosgrove MM, Perucho M, Arnheim N (1990) Detection of c-K-ras mutations in fine needle aspirates from human pancreatic adenocarcinomas. Cancer Res 50:1279-1283
17. Tada M, Omata M, Onto M (1991) Clinical application of ras gene mutation for diagnosis of pancreatic adenocarcinoma. Gastroenterology 100:233-238
18. Evans DB, Frazier ML, Charnsangavej C, Katz RL, Larry L, Abbruzzese JL (1996) Molecular diagnosis of exocrine pancreatic cancer using a percutaneous technique. Ann Surg Oncol 3:241-246
19. Villanueva A, Reyes G, Cuatrecasas M, Martinez A, Erill N, Lerma E, Farre A, Lluis F, Capella G (1996) Diagnostic utility of K-ras mutations in fine-needle aspirates of pancreatic masses. Gastroenterology 110:1587-1594
20. Watanabe H, Sawabu N, Songur Y, Yamaguchi Y, Yamakawa O, Satomura Y, Ohta H, Motoo Y, Okai T, Wakabayashi T (1996) Detection of K-ras point mutations at codon 12 in pure pancreatic juice for the diagnosis of pancreatic cancer by PCR-RFLP analysis. Pancreas 12:18-24
21. Wakabayashi T, Sawabu N, Watanabe H, Morimoto H, Sugioka G, Takita Y (1996) Detection of K-ras point mutation at codon 12 in pure pancreatic juice collected 3 years and 6 months before the clinical diagnosis of pancreatic cancer. Am J Gastroenterol 91:1848-1851
22. Tada M, Omata M, Kawai S, Saisho H, Ohto M, Saiki RK, Sninsky JJ (1993) Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res 53:2472-2474
23. Miki H, Matsumoto S, Harada H, Mori S, Haba R, Ochi K, Kobayashi S, Ohmori M (1993) Detection of c-Ki-ras point mutation from pancreatic juice. A useful diagnostic approach for pancreatic carcinoma. Int J Pancreatol 14:145-148
24. Caldas C, Hahn SA, Hruban RH, Redston MS, Yeo CJ, Kern SE (1994) Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 54:3568-3573
25. Yanagisawa A, Ohtake K, Ohashi K, Hori M, Kitagawa T, Sugano H, Kato Y (1993) Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. Cancer Res 53:953-956
26. Pellegata NS, Sessa F, Renault B, Bonato M, Leone BE, Solcia E, Ranzani GN (1994) K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 54:1556-1560
27. Rivera JA, Rail CJN, Graeme Cook F, Fernandez del Castillo C, Shu P, Lakey N, Tepper R, Rattner DW, Warshaw AL, Rustgi AK (1997) Analysis of K-ras oncogene mutations in chronic pancreatitis with ductal hyperplasia. Surgery 121:42-49
28. Tada M, Ohashi M, Shiratori Y, Okudaira T, Komatsu Y, Kawabe T, Yoshida H, Machinami R, Kishi K, Omata M (1996) Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology 110: 227-231
29. Lowenfels AB, Manisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR, DiMagno EP, Andren-Sandberg A, Domellof L (1993) Pancreatitis and the risk of pancreatic cancer. International pancreatitis study group. N Engl J Med 328:1433-1437
30. Furuya N, Kawa S, Akamatsu T, Furihata K (1997) Long-term follow-up of patients with chronic pancreatitis and K-ras gene mutation detected in pancreatic juice. Gastroenterology 113:593-598
31. Burns J, Barton C, Wynford-Thomas D, Lemoine N (1993) In vitro transformation of epithelial cells by ras oncogenes. Epithelial Cell Biol 2:26-43
32. Moskaluk CA, Hruban RH, Kern SE (1997) p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 57:2140-2143
33. Slebos RJC, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, Meijer CJLM, Wagenaar SS, Vanderschueren RGJRA, van Zandwijk N, Mooi WJ, Bos JL, Rodenhuis S (1990) K-Ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323:561-565
34. Silini EM, Bosi F, Pellegata NS, Volpato G, Romano A, Nazari S. Tinelli C, Ranzani GN, Solcia E, Fiocca R (1994) K-ras gene mutations: an unfavorable prognostic marker in stage I lung adenocarcinoma. Virchows Arch 424:367-373
35. Benhattar J, Losi L, Chaubert P, Givel JC, Costa J (1993) Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology 104:1044-1048
36. Moerkerk P, Arends JW, van Driel M, de Bruine A, de Goeij A, ten Kate J (1994) Type and number of Ki-ras point mutations relate to stage of human colorectal cancer. Cancer Res 54: 3376-3378
37. Hruban RH, van Mansfeld ADM, Offerhaus GJA, van Weering DK, Allison DC, Goodman SN, Kensler TW, Bose KK, Cameron JL, Bos JL (1993) K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 143:545-554
38. Motojima K, Urano T, Nagata Y, Shiku H, Tsunoda T, Kanematsu T (1991) Mutations in the Kirsten-ras oncogene are common but lack correlation with prognosis and tumor stage in human pancreatic carcinoma. Am J Gastroenterol 86:1784-1788
39. Schaeffer BK, Glasner S, Kuhlmann E, Myles JL, Longnecker DS (1994) Mutated c-K-ras in small pancreatic adenocarcinomas. Pancreas 9:161-165
40. Wiley LM, Adamson ED, Tsark EC (1995) Epidermal growth factor receptor function in early mammalian development. Bioessays 17:839-846
41. Korc M, Meltzer P, Trent J (1986) Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer. Proc Natl Acad Sci U S A 83:5141-5144
42. Lemoine NR, Hughes CM, Barton CM, Poulsom R, Jeffery RE, Kloppel G, Hall PA, Gullick WJ (1992) The epidermal growth factor receptor in human pancreatic cancer. J Pathol 166:7-12
43. Carraway KLIII, Cantley LC (1994) A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell 78:5-8
44. Earp HS, Dawson TL, Li X, Yu H (1995) Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research Breast Cancer Res Treat 35:115-132
45. Carpenter G, Cohen S (1976) Human epidermal growth factor and the proliferation of human firoblasts. J Cell Physiol 88: 227-237
46. Ohlsson B, Jansen C, Ihse I, Axelson J (1997) Epidermal growth factor induces cell proliferation in mouse pancreas and salivary glands. Pancreas 14:94-98
47. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG, Korc M (1993) Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 13:565-569
48. Barton CM, Hall PA, Hughes CM, Gullick WJ, Lemoine NR (1991) Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J Pathol 163:111-116
49. Ebert M, Yokoyama M, Kobrin MS, Friess H, Lopez ME, Buchler MW, Johnson GR, Korc M (1994) Induction and expression of amphiregulin in human pancreatic cancer. Cancer Res 54:3959-3962
50. Yokoyama M, Ebert M, Funatomi H, Friess H, Buchler MW, Johnson GR, Korc M (1995) Amphiregulin is a potent mitogen in human pancreatic cancer cells: correlation with patient survival. Int J Oncol 6:625-631
51. Funatomi H, Itakura J, Ishiwata T, Pastan I, Thompson SA, Johnson GR, Korc M (1997) Amphiregulin antisense oligonucleotide inhibits the growth of T3M4 human pancreatic cancer cells and sensitizes the cells to EGF receptor-targeted therapy. Int J Cancer 72:512-517
52. Yokoyama M, Funatomi H, Hope C, Damm D, Friess H, Buchler MW, Abraham J, Korc M (1996) Heparin-binding EGF-like growth factor expression and biological action in human pancreatic cancer cells. Int J Oncol 8:289-295
53. Toyoda H, Komurasaki T, Uchida D, Takayama Y, Isobe T, Okuyama T, Hanada K (1995) Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes. J Biol Chem 270:7495-7500
54. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchler M, Beger HG (1992) Overexpression of the epidermal growth-factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth-factor and transforming growth-factor-alpha. J Clin Invest 90:1352-1360
55. Kraus MH, Issing W, Miki T, Popescu NC, Aaronson SA (1989) Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci U S A 86:9193-9197
56. Plowman GD, Culouscou JM, Whitney GS, Green JM, Carlton GW, Foy L, Neubauer MG, Shoyab M (1993) Ligand-specific activation of HER4/p180erbB4. a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 90:1746-1750
57. Shing Y, Christofori G, Hanahan D, Ono Y, Sasada R, Igarashi K, Folkman J (1993) Betacellulin: a mitogen from pancreatic beta cell tumors. Science 259:1604-1607
58. Hall PA, Hughes CM, Staddon SL, Richman PI, Gullick WJ, Lemoine NR (1990) The c-erbB-2 proto-oncogene in human pancreatic cancer. J Pathol 161:195-200
59. Lemoine NR, Lobresco M, Leung H, Barton C, Hughes CM, Prigent SA, Gullick WJ, Kloppel G (1992) The erbB-3 gene in human pancreatic cancer. J Pathol 168:269-273
60. Maguire HC Jr, Greene MI (1989) The neu (c-erbB-2) oncogene. Semin Oncol 16:148-155
61. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Kunz J, Beger HG, Korc M (1993) Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum Pathol 24:1127-1134
62. Jaskiewicz K, Krige JEJ, Thomsom J (1994) Expression of p53 tumor suppressor gene, oncoprotein c-erbB-2, cellular proliferation and differentiation in malignant and benign pancreatic lesions. Anticancer Res 14:1919-1922
63. Satoh K, Sasano H, Shimosegawa T, Koizumi M, Yamazaki T, Mochizuki F, Kobayashi N, Okano T, Toyota T, Sawai T (1993) An immunohistochemical study of the c-erbB-2 oncogene product in intraductal mucin-hypersecreting neoplasms and in ductal cell carcinomas of the pancreas. Cancer 72:51-56
64. Dugan MC, Dergham ST, Kucway R, Singh K, Biernat L, Du W, Vaitkevicius VK, Crissman JD, Sarkar FH (1997) HER-2/neu expression in pancreatic adenocarcinoma: relation to tumor differentiation and survival. Pancreas 14:229-236
65. Friess H, Yamanaka Y, Kobrin MS, Do DA, Buchler MW, Korc M (1995) Enhanced erbB-3 expression in human pancreatic cancer correlates with tumour progression. Clin Cancer Res 1:1413-1420
66. Matsumoto K, Nakamura T (1996) Emerging multipotent aspects of hepatocyte growth factor. J Biochem (Tokyo) 119: 591-600
67. Weidner KM, Sachs M, Birchmeier W (1993) The Met receptor tyrosme kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor. J Cell Biol 121:145-154
68. Jiang WG, Hiscox S (1997) Hepatocyte growth factor/scatter factor, a cytokine playing multiple and converse roles. Histol Histopathol 12:537-555
69. Ebert M, Yokoyama M, Friess H, Buchler MW, Korc M (1994) Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer. Cancer Res 54: 5775-5778
70. Tsuda H, Iwase T, Matsumoto K, Ito M, Hirono I, Nishida Y, Yamamoto M, Tatematsu M, Matsumoto K, Nakamura T(1992) Immunohistochemical localization of hepatocyte growth factor protein in pancreas islet A-cells of man and rats. Jpn J Cancer Res 83:1262-1266
71. Di Renzo MF, Poulsom R, Olivero M, Comoglio PM, Lemoine NR (1995) Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res 55:1129-1138
72. Kiehne K, Herzig KH, Folsch UR (1997) c-met expression in pancreatic cancer and effects of hepatocyte growth factor on pancreatic cancer cell growth. Pancreas 15:35-40
73. Furukawa T, Duguid WP, Kobari M, Matsuno S, Tsao MS (1995) Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis. Am J Pathol 147:889-895
74. Massague J (1990) The transforming growth factor-β family. Ann Rev Cell Biol 6:597-641
75. Massague J, Cheifetz S, Laiho M, Ralph DA, Weis FMB, Zentella A (1992) Transforming growth factor-β. Cancer Surv 12:81-103
76. Lawrence DA (1996) Transforming growth factor-beta: a general review. Eur Cytokine Netw 7:363-374
77. Gold LI, Korc M (1994) Expression of transforming growth factor-β1, 2, and 3 mRNA and protein in human cancers. Dig Surg 11:150-156
78. Friess H, Yamanaka Y, Buchler M, Ebert M, Beger HG, Gold LI, Korc M (1993) Enhanced expression of transforming growth-factor-beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 105:1846-1856
79. van Laethem JL, Resibois A, Rickaert F, Deviere J, Gelin M, Cremer M, Robberecht P (1997) Different expression of transforming growth factor β1 in pancreatic ductal adenocarcinoma and cystic neoplasms. Pancreas 15:41-47
80. Friess H, Yamanaka Y, Buchler M, Beger HG, Kobrin MS, Baldwin RL, Korc M (1993) Enhanced expression of the type II transforming growth factor beta receptor in human pancreatic cancer cells without alteration of type III receptor expression. Cancer Res 53:2704-2707
81. Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, Laiho M, Wang XF, Massague J (1992) TGF beta signals through a heteromeric protein kinase receptor complex. Cell 71: 1003-1014
82. Friesel RE, Maciag T (1995) Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB J 9:919-925
83. Gospodarowicz D, Neufeld G, Schweigerer L (1986) Molecular and biological characterization of fibroblast growth factor, an angiogenic factor which also controls the proliferation and differentiation of mesoderm and neuroectoderm derived cells. Cell Differ 19:1-17
84. Leung HY, Hughes CM, Kloppel G, Williamson RCN, Lemoine NR (1994) Localization of expression of fibroblast growth factors and their receptors in pancreatic adenocarcinoma by insitu hybridization. Int J Oncol 4:1219-1223
85. Friess H, Yamanaka Y, Buchler M, Beger HG, Do DA, Kobrin MS, Korc M (1994) Increased expression of acidic and basic fibroblast growth factors in chronic pancreatitis. Am J Pathol 144:117-128
86. Yamanaka Y, Friess H, Buchler M, Beger HG, Uchida E, Onda M, Kobrin MS, Korc M (1993) Overexpression of acidic and basic fibroblast growth-factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res 53:5289-5296
87. Johnson DE, Williams LT (1993) Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 60:1-41
88. Burgess WH, Maciag T (1989) Theheparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem 58: 575-606
89. Leung HY, Gullick WJ, Lemoine NR (1994) Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer. Int J Cancer 59:667-675
90. Yamazaki K, Nagao T, Yamaguchi T, Saisho H, Kondo Y (1997) Expression of basic fibroblast growth factor (FGF-2)-associated with tumour proliferation in human pancreatic carcinoma. Virchows Arch 431:95-101
91. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW (1991) The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5:1806-1814
92. Ferrara N, Houck K, Jakeman L, Leung DW (1992) Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 13:18-32
93. Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NP, Risau W, Ullrich A (1993) High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72:835-846
94. Senger DR, Perruzzi CA, Feder J, Dvorak HF (1986) A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 46:5629-5632
95. Christofori G, Naik P, Hanahan D (1995) Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol Endocrinol 9:1760-1770
96. Rooman I, Schuit F, Bouwens L (1997) Effect of vascular endothelial growth factor on growth and differentiation of pancreatic ductal epithelium. Lab Invest 76:225-232
97. Itakura J, Ishiwata T, Friess H, Fujii H, Matsumoto Y, Buchler MW, Korc M (1997) Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res 3:1309-1316
98. Bollag W, Holdener EE (1992) Retinoids in cancer prevention and therapy. Ann Oncol 3:513-526
99. Sporn MB, Roberts AB (1983) Role of retinoids in differentiation and carcinogenesis. Cancer Res 43:3034-3040
100. Leid M, Kastner P, Chambon P (1992) Multiplicity generates diversity in the retinoic acid pathway. Trends Biochem Sci 17:427-433
101. Giguere V (1994) Retinoic acid receptors and cellular retinoid binding proteins: complex interplay in retinoid signaling. Endocr Rev 15:61-79
102. Colston KW (1993) New concepts in hormone receptor action. Lancet 342:67-68
103. Zugmaier G, Jager R, Grage B, Gottardis MM, Havemann K, Knabbe C (1996) Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells. Br J Cancer 73:1341-1346
104. 1 integrin receptor. Gastroenterology 112:532-542
105. Xu XC, Stier U, Rosewicz S, El-Naggar AK, Lotan R (1996) Differential suppression of nuclear retinoic acid receptor beta in pancreatic carcinomas. Int J Oncol 8:445-451
106. Kaiser A, Herbst H, Fisher G, Koenigsmann M, Berdel WE, Riecken EO, Rosewicz S (1997) Retinoic acid receptor β regulates growth and differentiation in human pancreatic carcinoma cells. Gastroenterology 113:920-929
107. Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, Tsichlis PN, Testa JR (1992) AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 89:9267-9271
108. Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK, Kaplan DR, Tsichlis PN (1995) The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81:727-736
109. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, Testa JR (1996) Amplification of AKT2 in human pancreatic cancer cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA 93:3636-3641
110. Ruggeri B, Zhang SY, Caamano J, DiRado M, Flynn SD, Klein-Szanto AJP (1992) Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. Oncogene 7:1503-1511
111. Barton CM, Staddon SL, Hughes CM, Hall PA, O'Sullivan C, Kloppel G, Theis B, Russell RCG, Neoptolemos J, Williamson RCN, Land DP, Lemoine NR (1991) Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 64:1076-1082
112. Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, Iacono C, Hirohashi S (1993) Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 142:1534-1543
113. Casey G, Yamanaka Y, Friess H, Kobrin MS, Lopez ME, Buchler M, Beger HG, Korc M (1993) p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett 69:151-160
114. Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ, Kern SE (1994) p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 54:3025-3033
115. Suwa H, Ohshio G, Okada N, Wang Z, Fukumoto M, Imamura T, Imamura M (1997) Clinical significance of serum p53 antigen in patients with pancreatic carcinomas. Gut 40:647-653
116. Luo JC, Neugut AI, Garbowski G, Forde KA, Treat M, Smith S, Carney WP, Brandt-Rauf PW (1995) Levels of p53 antigen in the plasma of patients with adenomas and carcinomas of the colon. Cancer Lett 91:235-240
117. Fontanini G, Fiore L, Bigini D, Vignati S, Calvo S, Mussi A, Lucchi M, Angeletti CA, Merlo GR, Basolo F (1994) Levels of p53 antigen in the serum of non-small lung cancer patients correlate with positive p53 immunohistochemistry on tumor sections, tumor necrosis and nodal involvement. Int J Oncol 5:553-558
118. Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell cycle causing specific inhibition of cyclin D/CDK4. Nature 366:704-707
119. Huang L, Goodrow TL, Zhang SY, Klein-Szanto AJP, Chang H, Ruggeri BA (1996) Deletion and mutation analyses of the p16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. Cancer Res 56:1137-1141
120. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeo CJ, Kern SE (1997) Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 57:1731-1734
121. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte-Waldhoff I, Schmiegel W, Baylin SB, Kern SE, Herman JG (1997) Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 57:3126-3130
122. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PAT, Ally DS, Sheahan MD, Clark WH Jr, Tucker MA, Dracopoli NC (1994) Germline p16 mutations in familial melanoma. Nat Genet 8:15-21
123. Nancarrow DJ, Mann GJ, Holland EA, Walker GJ, Beaton SC, Walters MK, Luxford C, Palmer JM, Donald JA, Weber JL, Fountain JW, Kefford RF, Hayward NK (1993) Confirmation of chromosome 9p linkage in familial melanoma. Am J Hum Genet 53: 936-942
124. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753-756
125. Naumann M, Savitskaia N, Eilert C, Schramm A, Kalthoff H, Schmiegel W (1996) Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Gastroenterolosy 110:1215-1224
126. Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, Weinstein CL, Bova GS, Isaccs WB, Cairns P, Nawroz H, Sidransky D, Casero RA Jr, Meltzer PS, Hahn SA, Kern SE (1996) DPC4 gene in various tumor types. Cancer Res 56:2527-2530
127. Hahn SA, Schutte M, Hoque AT, Moskaluk Ca, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271:350-353
128. 1) induced growth inhibition and transcriptional response in breast tumour cells. Oncogene 14:1891-1899
129. Liu F, Hata A, Baker JC, Doody J, Carcamo J, Harland RM, Massgue J (1996) A human Mad protein acting as a BMP-regulated transcriptional activator. Nature 381:620-623
130. Moskaluk CA, Hruban RH, Schutte M, Lietman AS, Smyrk T, Furaro L, Fusaro R, Lynch J, Yeo CJ, Jackson CE, Lynch HT, Kern SE (1997) Genomic sequencing of DPC4 in the analysis of familial pancreatic carcinoma. Diagn Mol Pathol 6:85-90
131. Barton CM, McKie AB, Hogg A, Bia B, Elia G, Phillips SMA, Ding SF, Lemoine NR (1995) Abnormalities of the RB1 and DCC tumor suppressor genes: uncommon in human pancreatic adenocarcinoma. Mol Carcinog 13:61-69
132. Hiyama E, Kodama T, Shinbara K, Iwao T, Itoh M, Hiyama K, Shay JW, Matsuura Y, Yokoyama T (1997) Telomerase activity is detected in pancreatic cancer but not in benign tumors. Cancer Res 57:326-331
133. Suehara N, Mizumoto K, Muta T, Tominaga Y, Shimura H, Kitajima S, Hamasaki N, Tsuneyoshi M, Tanaka M (1997) Telomerase elevation in pancreatic ductal carcinoma compared to nonmalignant pathological states. Clin Cancer Res 3:993-998
134. Stetler-Stevenson WG, Liotta LA, Kleiner DE Jr (1993) Extra-cellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 7:1434-1441
135. Zucker S, Wieman JM, Lysik RM, Wilkie D, Ramamurthy NS, Golub LM, Lane B (1987) Enrichment of collagen and gelatin degrading activities in the plasma membranes of human cancer cells. Cancer Res 47:1608-1614
136. Zucker S, Moll UM, Lysik RM, DiMassimo EI, Stetler-Stevenson WG, Liotta LA, Schwedes JW (1990) Extraction of type-IV collagenase/gelatinase from plasma membranes of human cancer cells. Int J Cancer 45:1137-1142
137. Bramhall SR, Stamp GWH, Dunn J, Lemoine NR, Neoptolemos JP (1996) Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease. Br J Cancer 73:972-978
138. Bramhall SR, Neoptolemos JP, Stamp GWH, Lemoine NR (1997) Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J Pathol 182:347-355
139. Jimi SI, Shono T, Ono M, Kuwano M, Tanaka M, Lopez Otin C, Kono A (1997) Expression of matrix metalloproteinases 1 and 2 genes in a possible association with metastatic abilities of human pancreatic cancer cells. Int J Oncol 10:623-628
140. Zervos EE, Norman JG, Gower WR, Franz MG, Rosemurgy AS (1997) Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo. J Surg Res 69:367-371
141. Takeuchi Y, Nakao A, Harada A, Nonami T, Fukatsu T, Takagi H (1993) Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study. Am J Gastroenterol 88:1928-1933
142. Cantero D, Friess H, Deflorin J, Zimmermann A, Brundler MA, Riesle E, Korc M, Buchler MW (1997) Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer 75:388-395
143. Griffin CA, Hruban RH, Morsberger LA, Ellinaham T, Long PP, Jaffee EM, Hauda KM, Bohlander SK, Yeo CJ (1995) Consistent chromosome abnormalities in adenocarcinoma of the pancreas. Cancer Res 55:2394-2399
144. Brat DJ, Hahn SA, Griffin CA, Yeo CJ, Kern SE, Hruban RH (1997) The structural basis of molecular genetic deletions. An integration of classical cytogenetic and molecular analyses in pancreatic adenocarcinoma. Am J Pathol 150:383-391